readthroughSign in
CompanyINMNasdaqVancouver

InMed Pharmaceuticals Inc.

InMed Pharmaceuticals develops small molecule CB1/CB2 receptor antagonists for Alzheimer's disease, ocular, and dermatological indications.

SCHEDULE 13G/ANov 16Latest SEC filing
Nov 16Latest story